BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15906027)

  • 1. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
    Oved K; Lev A; Noy R; Segal D; Reiter Y
    Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
    Lev A; Novak H; Segal D; Reiter Y
    J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules.
    Noy R; Haus-Cohen M; Oved K; Voloshin T; Reiter Y
    Mol Cancer Ther; 2015 Jun; 14(6):1327-35. PubMed ID: 25852061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
    Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
    J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
    J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
    Lev A; Noy R; Oved K; Novak H; Segal D; Walden P; Zehn D; Reiter Y
    Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9051-6. PubMed ID: 15184663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
    Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
    J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of human cytotoxic T cells with HIV-1-derived peptides presented by recombinant HLA-A2 peptide complexes.
    Walter JB; Brander C; Mammen M; Garboczi DN; Kalams SA; Whitesides GM; Walker BD; Eisen HN
    Int Immunol; 1997 Mar; 9(3):451-9. PubMed ID: 9088983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
    Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
    Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells.
    Jantscheff P; Spagnoli G; Zajac P; Rochlitz CF
    Cancer Immunol Immunother; 2002 Sep; 51(7):367-75. PubMed ID: 12192536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular studies of anti-HLA-A2 using light-chain shuffling: a structural model for HLA antibody binding.
    Watkins NA; Dafforn TR; Kuijpers M; Brown C; Javid B; Lehner PJ; Navarrete C; Ouwehand WH
    Tissue Antigens; 2004 Apr; 63(4):345-54. PubMed ID: 15009806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.